Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea

Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 wer...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 23; no. 1; pp. 1 - 8
Main Authors Han, Jung-Yong, Kim, Hyoungyoung, Jung, Sun-Young, Jang, Eun Jin, Cho, Soo-Kyung, Sung, Yoon-Kyoung
Format Journal Article
LanguageEnglish
Published London BioMed Central 27.10.2021
BioMed Central Ltd
BMC
Subjects
Arthritis
Blood cancer
Cancer
Cohort analysis
Complications and side effects
Gender
Incidence rate
Leukemia
Lupus
Lymphoma
Malignancy
Medicine
Medicine & Public Health
Orthopedics
Population
Population-based studies
Prostate
Reproductive system
Research Article
Rheumatology
Risk factors
Standardised incidence ratio
Statistics
Systemic lupus erythematosus
Thyroid cancer
Thyroid gland
Womens health
South Korea
Malignancy
Systemic lupus erythematosus
Incidence rate
Standardised incidence ratio
Online AccessGet full text
ISSN1478-6362
1478-6354
1478-6362
DOI10.1186/s13075-021-02648-y

Cover

Abstract Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated. Results We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6–1.9), 1.7 (95% CI 1.5–1.8), and 5.9 (95% CI 4.8–7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1–4.2), bladder (2.4, 95% CI 1.1–3.8), liver (1.9, 95% CI 1.4–2.3), pancreas (1.9, 95% CI 1.3–2.6), lung (1.8, 95% CI 1.2–2.4), colon (1.7, 95% CI 1.3–2.2), thyroid (1.6, 95% CI 1.3–1.8) and breast and reproductive system (1.5, 95% CI 1.2–1.7) cancers are at increased risk in SLE patients. Conclusion An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
AbstractList Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated. Results We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6–1.9), 1.7 (95% CI 1.5–1.8), and 5.9 (95% CI 4.8–7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1–4.2), bladder (2.4, 95% CI 1.1–3.8), liver (1.9, 95% CI 1.4–2.3), pancreas (1.9, 95% CI 1.3–2.6), lung (1.8, 95% CI 1.2–2.4), colon (1.7, 95% CI 1.3–2.2), thyroid (1.6, 95% CI 1.3–1.8) and breast and reproductive system (1.5, 95% CI 1.2–1.7) cancers are at increased risk in SLE patients. Conclusion An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE.BACKGROUNDThis study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE.We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated.METHODSWe conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated.We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6-1.9), 1.7 (95% CI 1.5-1.8), and 5.9 (95% CI 4.8-7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1-4.2), bladder (2.4, 95% CI 1.1-3.8), liver (1.9, 95% CI 1.4-2.3), pancreas (1.9, 95% CI 1.3-2.6), lung (1.8, 95% CI 1.2-2.4), colon (1.7, 95% CI 1.3-2.2), thyroid (1.6, 95% CI 1.3-1.8) and breast and reproductive system (1.5, 95% CI 1.2-1.7) cancers are at increased risk in SLE patients.RESULTSWe identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6-1.9), 1.7 (95% CI 1.5-1.8), and 5.9 (95% CI 4.8-7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1-4.2), bladder (2.4, 95% CI 1.1-3.8), liver (1.9, 95% CI 1.4-2.3), pancreas (1.9, 95% CI 1.3-2.6), lung (1.8, 95% CI 1.2-2.4), colon (1.7, 95% CI 1.3-2.2), thyroid (1.6, 95% CI 1.3-1.8) and breast and reproductive system (1.5, 95% CI 1.2-1.7) cancers are at increased risk in SLE patients.An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.CONCLUSIONAn increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated. We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6-1.9), 1.7 (95% CI 1.5-1.8), and 5.9 (95% CI 4.8-7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1-4.2), bladder (2.4, 95% CI 1.1-3.8), liver (1.9, 95% CI 1.4-2.3), pancreas (1.9, 95% CI 1.3-2.6), lung (1.8, 95% CI 1.2-2.4), colon (1.7, 95% CI 1.3-2.2), thyroid (1.6, 95% CI 1.3-1.8) and breast and reproductive system (1.5, 95% CI 1.2-1.7) cancers are at increased risk in SLE patients. An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated. Results We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6-1.9), 1.7 (95% CI 1.5-1.8), and 5.9 (95% CI 4.8-7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1-4.2), bladder (2.4, 95% CI 1.1-3.8), liver (1.9, 95% CI 1.4-2.3), pancreas (1.9, 95% CI 1.3-2.6), lung (1.8, 95% CI 1.2-2.4), colon (1.7, 95% CI 1.3-2.2), thyroid (1.6, 95% CI 1.3-1.8) and breast and reproductive system (1.5, 95% CI 1.2-1.7) cancers are at increased risk in SLE patients. Conclusion An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population. Keywords: Systemic lupus erythematosus, Malignancy, Incidence rate, Standardised incidence ratio
Abstract Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated. Results We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6–1.9), 1.7 (95% CI 1.5–1.8), and 5.9 (95% CI 4.8–7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1–4.2), bladder (2.4, 95% CI 1.1–3.8), liver (1.9, 95% CI 1.4–2.3), pancreas (1.9, 95% CI 1.3–2.6), lung (1.8, 95% CI 1.2–2.4), colon (1.7, 95% CI 1.3–2.2), thyroid (1.6, 95% CI 1.3–1.8) and breast and reproductive system (1.5, 95% CI 1.2–1.7) cancers are at increased risk in SLE patients. Conclusion An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated. Results We identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6–1.9), 1.7 (95% CI 1.5–1.8), and 5.9 (95% CI 4.8–7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1–4.2), bladder (2.4, 95% CI 1.1–3.8), liver (1.9, 95% CI 1.4–2.3), pancreas (1.9, 95% CI 1.3–2.6), lung (1.8, 95% CI 1.2–2.4), colon (1.7, 95% CI 1.3–2.2), thyroid (1.6, 95% CI 1.3–1.8) and breast and reproductive system (1.5, 95% CI 1.2–1.7) cancers are at increased risk in SLE patients. Conclusion An increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.
ArticleNumber 270
Audience Academic
Author Han, Jung-Yong
Kim, Hyoungyoung
Cho, Soo-Kyung
Jang, Eun Jin
Sung, Yoon-Kyoung
Jung, Sun-Young
Author_xml – sequence: 1
  givenname: Jung-Yong
  surname: Han
  fullname: Han, Jung-Yong
  organization: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases
– sequence: 2
  givenname: Hyoungyoung
  surname: Kim
  fullname: Kim, Hyoungyoung
  organization: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases
– sequence: 3
  givenname: Sun-Young
  surname: Jung
  fullname: Jung, Sun-Young
  organization: College of Pharmacy, Chung-Ang University
– sequence: 4
  givenname: Eun Jin
  surname: Jang
  fullname: Jang, Eun Jin
  organization: Department of Information Statistics, Andong National University
– sequence: 5
  givenname: Soo-Kyung
  surname: Cho
  fullname: Cho, Soo-Kyung
  organization: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases
– sequence: 6
  givenname: Yoon-Kyoung
  surname: Sung
  fullname: Sung, Yoon-Kyoung
  email: sungyk@hanyang.ac.kr
  organization: Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases
BookMark eNp9kktv1DAUhSNURB_wB1hZYsMmxW87LJCqiseISmxgbXkce8YlsYPtFOXf45mpKFOhKopi2ed8N_f6nDcnIQbbNK8RvERI8ncZEShYCzGqL6eyXZ41Z4gK2XLC8ck_69PmPOdbCDHuMH3RnBIqIBcCnzVpFUyyOtseJJ9_gujAqAe_CTqYBfgAJl28DSWD375sQV5ysaM3YJinOQOblrK1oy4xz_k9mOI0D1UfQ7veI03cxlRALnO_h32NtdbL5rnTQ7av7r8XzY9PH79ff2lvvn1eXV_dtIZJWup_Ewl7RCWBRuOeQkSpk9QyB7XuGOVkzZ3A2nLNJVsToRGGTvSSMNoJC8lFszpw-6hv1ZT8qNOiovZqvxHTRulUvBmsQnV-sDcOUt5T3XUdEhpKjDBm3FLpKuvDgTXN69H2pk4k6eEIenwS_FZt4p2SjDFIuwp4ew9I8ddsc1Gjz8YOgw42zllhJoXgjDNZpW8eSW_jnEIdVVV1UnaEYPSg2ujagA8u1rpmB1VXXCJO6-BIVV3-R1WffneLNU7O1_0jAz4YTIo5J-v-9oig2qVOHVKnaurUPnVqqSb5yGR82eegVvPD01ZysOZaJ2xsemj2CdcfmJzsng
CitedBy_id crossref_primary_10_1016_j_autrev_2023_103444
crossref_primary_10_3390_cells12172192
crossref_primary_10_1080_03009742_2025_2467556
crossref_primary_10_25122_jml_2023_0314
crossref_primary_10_1038_s41598_022_24324_0
crossref_primary_10_1186_s12935_023_03143_x
crossref_primary_10_4078_jrd_2023_0037
crossref_primary_10_3390_rheumato4040017
crossref_primary_10_1016_j_ard_2025_01_026
crossref_primary_10_1016_j_oooo_2023_07_007
crossref_primary_10_1111_head_14501
crossref_primary_10_1097_MD_0000000000038511
crossref_primary_10_3389_fneur_2024_1420201
crossref_primary_10_3389_fonc_2023_1170119
crossref_primary_10_1186_s13075_025_03482_2
crossref_primary_10_1093_ckj_sfae376
Cites_doi 10.1191/0961203305lu2180xx
10.1016/j.semarthrit.2019.11.007
10.1002/art.34473
10.1007/s00296-012-2426-0
10.1016/j.jaut.2012.12.009
10.1038/nrrheum.2016.23
10.1177/0961203319826672
10.7314/APJCP.2012.13.12.6163
10.1186/s13075-018-1760-3
10.1177/0961203309345777
10.1038/nrrheum.2014.36
10.1136/ard.2006.067108
10.7326/M17-0102
10.1016/j.berh.2017.09.013
10.1177/096120330000900711
10.1136/ard.52.9.659
10.1191/0961203306lu2305xx
10.1177/0961203317707825
10.1002/art.38731
10.1016/j.semarthrit.2017.03.022
10.1002/art.21955
10.1002/art.1780400928
10.1007/s10067-009-1332-7
10.1093/rheumatology/keaa267
10.3899/jrheum.101190
10.1016/j.amjmed.2010.08.006
10.1002/art.39594
ContentType Journal Article
Copyright The Author(s) 2021
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021. The Author(s).
Copyright_xml – notice: The Author(s) 2021
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021. The Author(s).
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s13075-021-02648-y
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic



Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Statistics
EISSN 1478-6362
EndPage 8
ExternalDocumentID oai_doaj_org_article_10260dcf046d4a99917a08212256e48f
PMC8555049
A681644833
10_1186_s13075_021_02648_y
GeographicLocations South Korea
GeographicLocations_xml – name: South Korea
GrantInformation_xml – fundername: ministry of health & welfare, republic of korea
  grantid: HI19C1202
– fundername: ;
  grantid: HI19C1202
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
E3Z
EBD
EBLON
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
INH
INR
ITC
KQ8
M1P
O5R
O5S
O9-
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
AAYXX
ALIPV
CITATION
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c584t-63380d14830ca2d40144f84e5f0aa95463b6f72ae6a685b37a120f7d835497e03
IEDL.DBID 7X7
ISSN 1478-6362
1478-6354
IngestDate Wed Aug 27 01:31:48 EDT 2025
Thu Aug 21 18:20:55 EDT 2025
Fri Sep 05 07:49:45 EDT 2025
Fri Jul 25 22:33:11 EDT 2025
Tue Jun 17 21:31:37 EDT 2025
Tue Jun 10 20:37:11 EDT 2025
Thu Apr 24 23:12:25 EDT 2025
Tue Jul 01 04:00:58 EDT 2025
Sat Sep 06 07:28:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Malignancy
Systemic lupus erythematosus
Incidence rate
Standardised incidence ratio
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c584t-63380d14830ca2d40144f84e5f0aa95463b6f72ae6a685b37a120f7d835497e03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2598893321?pq-origsite=%requestingapplication%
PMID 34706772
PQID 2598893321
PQPubID 42876
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_10260dcf046d4a99917a08212256e48f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8555049
proquest_miscellaneous_2587765658
proquest_journals_2598893321
gale_infotracmisc_A681644833
gale_infotracacademiconefile_A681644833
crossref_primary_10_1186_s13075_021_02648_y
crossref_citationtrail_10_1186_s13075_021_02648_y
springer_journals_10_1186_s13075_021_02648_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-10-27
PublicationDateYYYYMMDD 2021-10-27
PublicationDate_xml – month: 10
  year: 2021
  text: 2021-10-27
  day: 27
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Arthritis research & therapy
PublicationTitleAbbrev Arthritis Res Ther
PublicationYear 2021
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References F Ceccarelli (2648_CR1) 2017; 47
MY Choi (2648_CR10) 2017; 31
YJ Lin (2648_CR24) 2009; 18
J Lee (2648_CR15) 2017; 46
S Bernatsky (2648_CR28) 2006; 54
YJ Chen (2648_CR19) 2010; 123
MG Tektonidou (2648_CR5) 2016; 68
MC Hochberg (2648_CR16) 1997; 40
PW Noble (2648_CR25) 2016; 12
G Thomas (2648_CR29) 2014; 66
L Song (2648_CR12) 2018; 20
HJ Seo (2648_CR17) 2012; 13
S Bashir (2648_CR23) 1993; 52
Z Li (2648_CR3) 2017; 26
H Kim (2648_CR6) 2020; 50
B Löfström (2648_CR22) 2007; 66
M Petri (2648_CR4) 2012; 64
CY Hsu (2648_CR9) 2017; 56
KY Kang (2648_CR14) 2010; 29
2648_CR30
H Bateman (2648_CR21) 2000; 9
EY Yen (2648_CR8) 2017; 167
VM Ognenovski (2648_CR18) 2004; 31
S Bernatsky (2648_CR11) 2013; 42
BC Chun (2648_CR20) 2005; 14
EH Bae (2648_CR13) 2019; 28
N Danchenko (2648_CR2) 2006; 15
2648_CR7
LD Lyrio (2648_CR27) 2013; 33
B Löfström (2648_CR26) 2011; 38
References_xml – volume: 14
  start-page: 635
  issue: 8
  year: 2005
  ident: 2648_CR20
  publication-title: Korea. Lupus.
  doi: 10.1191/0961203305lu2180xx
– volume: 50
  start-page: 526
  issue: 3
  year: 2020
  ident: 2648_CR6
  publication-title: Semin Arthritis Rheum.
  doi: 10.1016/j.semarthrit.2019.11.007
– volume: 64
  start-page: 2677
  issue: 8
  year: 2012
  ident: 2648_CR4
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.34473
– volume: 33
  start-page: 335
  issue: 2
  year: 2013
  ident: 2648_CR27
  publication-title: Rheumatol Int.
  doi: 10.1007/s00296-012-2426-0
– volume: 42
  start-page: 130
  year: 2013
  ident: 2648_CR11
  publication-title: J Autoimmun.
  doi: 10.1016/j.jaut.2012.12.009
– volume: 12
  start-page: 429
  issue: 7
  year: 2016
  ident: 2648_CR25
  publication-title: Nat Rev Rheumatol.
  doi: 10.1038/nrrheum.2016.23
– volume: 28
  start-page: 317
  issue: 3
  year: 2019
  ident: 2648_CR13
  publication-title: Lupus.
  doi: 10.1177/0961203319826672
– volume: 46
  issue: 2
  year: 2017
  ident: 2648_CR15
  publication-title: South Korea. Int J Epidemiol.
– volume: 13
  start-page: 6163
  issue: 12
  year: 2012
  ident: 2648_CR17
  publication-title: Asian Pac J Cancer Prev.
  doi: 10.7314/APJCP.2012.13.12.6163
– volume: 56
  start-page: 620
  issue: 4
  year: 2017
  ident: 2648_CR9
  publication-title: Rheumatology (Oxford).
– volume: 20
  start-page: 270
  issue: 1
  year: 2018
  ident: 2648_CR12
  publication-title: Arthritis Res Ther.
  doi: 10.1186/s13075-018-1760-3
– volume: 18
  start-page: 1246
  issue: 14
  year: 2009
  ident: 2648_CR24
  publication-title: Lupus.
  doi: 10.1177/0961203309345777
– ident: 2648_CR30
  doi: 10.1038/nrrheum.2014.36
– volume: 66
  start-page: 1627
  issue: 12
  year: 2007
  ident: 2648_CR22
  publication-title: Ann Rheum Dis.
  doi: 10.1136/ard.2006.067108
– volume: 167
  start-page: 777
  issue: 11
  year: 2017
  ident: 2648_CR8
  publication-title: Ann Intern Med.
  doi: 10.7326/M17-0102
– volume: 31
  start-page: 373
  issue: 3
  year: 2017
  ident: 2648_CR10
  publication-title: Best Pract Res Clin Rheumatol.
  doi: 10.1016/j.berh.2017.09.013
– volume: 9
  start-page: 542
  issue: 7
  year: 2000
  ident: 2648_CR21
  publication-title: Lupus.
  doi: 10.1177/096120330000900711
– volume: 52
  start-page: 659
  issue: 9
  year: 1993
  ident: 2648_CR23
  publication-title: Ann Rheum Dis.
  doi: 10.1136/ard.52.9.659
– volume: 15
  start-page: 308
  issue: 5
  year: 2006
  ident: 2648_CR2
  publication-title: Lupus.
  doi: 10.1191/0961203306lu2305xx
– volume: 26
  start-page: 1127
  issue: 11
  year: 2017
  ident: 2648_CR3
  publication-title: Lupus.
  doi: 10.1177/0961203317707825
– volume: 66
  start-page: 2503
  issue: 9
  year: 2014
  ident: 2648_CR29
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.38731
– volume: 47
  start-page: 53
  issue: 1
  year: 2017
  ident: 2648_CR1
  publication-title: Semin Arthritis Rheum.
  doi: 10.1016/j.semarthrit.2017.03.022
– volume: 54
  start-page: 2550
  issue: 8
  year: 2006
  ident: 2648_CR28
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.21955
– volume: 40
  start-page: 1725
  issue: 9
  year: 1997
  ident: 2648_CR16
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.1780400928
– volume: 29
  start-page: 381
  issue: 4
  year: 2010
  ident: 2648_CR14
  publication-title: Clin Rheumatol.
  doi: 10.1007/s10067-009-1332-7
– volume: 31
  start-page: 1763
  issue: 9
  year: 2004
  ident: 2648_CR18
  publication-title: J Rheumatol.
– ident: 2648_CR7
  doi: 10.1093/rheumatology/keaa267
– volume: 38
  start-page: 1891
  issue: 9
  year: 2011
  ident: 2648_CR26
  publication-title: J Rheumatol.
  doi: 10.3899/jrheum.101190
– volume: 123
  start-page: 1150.e1
  issue: 12
  year: 2010
  ident: 2648_CR19
  publication-title: Am J Med.
  doi: 10.1016/j.amjmed.2010.08.006
– volume: 68
  start-page: 1432
  issue: 6
  year: 2016
  ident: 2648_CR5
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.39594
SSID ssj0022924
Score 2.4423923
Snippet Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a...
Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a...
This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. We conducted a retrospective nationwide...
This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE.BACKGROUNDThis study aimed to evaluate the...
Abstract Background This study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE. Methods We conducted a...
SourceID doaj
pubmedcentral
proquest
gale
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms Arthritis
Blood cancer
Cancer
Cohort analysis
Complications and side effects
Gender
Incidence rate
Leukemia
Lupus
Lymphoma
Malignancy
Medicine
Medicine & Public Health
Orthopedics
Population
Population-based studies
Prostate
Reproductive system
Research Article
Rheumatology
Risk factors
Standardised incidence ratio
Statistics
Systemic lupus erythematosus
Thyroid cancer
Thyroid gland
Womens health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hHhAXxFMEWmQkJA4Q4SSO7XBrEVUFKicq9WY5sQMrlWS12Rz233fGcRbSCrhwjZ2X5_kl428AXmfSSaW4TW1Z81RYBKy6zGXaVMS9jhHFhY3C51_l2YX4fFle_tbqi2rCJnrgaeHQqjHjdk2LOM4JS-mMshi2MtRD6YVuyfvyis9gKkKtHGHFvEVGy_cDempFO5EROlNJV7pbhKHA1n_bJ9-uk7zxszTEoNMHcD8mj-x4euiHcMd3j-Duefw9_hg2aO1UZO4do5Jx1rfsJ-bZ34lUY8dWHYssqgOjz69sYnFeNexqXI8D85vdROHaD-Pwga33rb3SOlySeulutiwQ0tLFvvR4rydwcfrp28ezNDZVSBvMNbapREzKHYKggjc2d4IQVauFL1tubRBQLVuVWy-t1GVdKJvlvFWOPhBVyvPiKRx0feefAfMt0XVxbdFNCJu1lXBaIF6pra6cK8oEsnmNTRMZx6nxxZUJyENLM8nFoFxMkIvZJfB2f8564tv46-wTEt1-JnFlhwOoQSZqkPmXBiXwhgRvyKLx8RobNybgSxI3ljmWOiMUWxQJHC5moiU2y-FZdUz0BINBeKkxJyzyLIFX-2E6k6rbOt-PNEcrhYl1qRNQC5VbvNlypFv9CGzgukSQKaoE3s3K-evmf1655_9j5V7AvZxsCkN5rg7hYLsZ_RHmaNv6ZTDHa4OXNVA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: SpringerOpen Free (Free internet resource, activated by CARLI)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkRAXRHmI0FK5EhIHiMjDr3ArK6qqqJyo1JvlxA6s1Carzeaw_74zTjYQCkhc43FeM2PPZ898BniTSieVSmxsRZnE3CJg1SKTcVUQ9zrOKC4UCl98lWeX_PxKXI00OVQL8-v-farlhw7HWEU1xAh6KRkr3t6HBwIvkjUv5GICVxkCiV1RzB_7zSaewM9_dxS-mxn52_ZomHVOn8DjMVxkJ4N-9-Geb57Cw4txQ_wZrNG_Ka3cO0ZJ4qyt2Q1G1t-JRmPLlg0beVM7RguubOBtXlbsul_1HfPr7UDa2nZ995GtpsO84jLckk7PXW9YoKClm31p8VnP4fL087fFWTweoxBXGF1sYokoNHEIe_KkspnjhKFqzb2oE2uDSkpZq8x6aaUWZa5smiW1crQkVCif5C9gr2kb_xKYr4mgK9EWBwZu07rgTnNEKKXVhXO5iCDd_WNTjRzjdNTFtQlYQ0sz6MWgXkzQi9lG8G7qsxoYNv4p_YlUN0kSO3a4gEZjRmfD7ojSXFUj9nfcUgisLIY6KY5d0nNdR_CWFG_Ih_H1KjuWIuBHEhuWOZE6Jdya5xEcziTR96p58850zOj7nUFAqTEKzLM0guOpmXpSPlvj255ktFIYSgsdgZqZ3OzL5i3N8kfg_9YCYSUvIni_M86fD__7n3v1f-IH8Cgj78FpOlOHsLdZ9_41xl-b8ig43i1svCed
  priority: 102
  providerName: Springer Nature
Title Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea
URI https://link.springer.com/article/10.1186/s13075-021-02648-y
https://www.proquest.com/docview/2598893321
https://www.proquest.com/docview/2587765658
https://pubmed.ncbi.nlm.nih.gov/PMC8555049
https://doaj.org/article/10260dcf046d4a99917a08212256e48f
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvZZ_MWxc0GOxhM_WHLMl7GWloKRstYyyQNyFbchvo7NSOH_Lf705WEryyvgQcSf7Q6U73k06_I-RjzA0XItKhzoooZBoAq8wSHpY5cq_DjGLcQeHLK34xZ98X2cIvuHU-rHJrE52hNk2Ja-Qn4KZLTA2fxN9WdyFmjcLdVZ9C4zE5jMETwdQNYrEHXEk-JLVlgJRgYmXbQzOSn3RguwWeTQYwjUFe4WY0MTn-_vtW-n7k5D_bp25WOn9Gjrw7SaeD_J-TR7Z-QZ5c-g3zl6QF_cewc2soBpHTpqJ_wPO-RpqNDV3W1POqdhQXZOnA67ws6W2_6jtq281A6tp0ffeVrnbJvsLC3RKz67Zr6ihq8WY_GnjWKzI_P_s9uwh9moWwBO9jDT2TysgALEqjUieGIcaqJLNZFWntRFbwSiTacs1lVqRCx0lUCYNLRrmwUfqaHNRNbd8Qaisk8IqkBsPBdFzlzEgGCKbQMjcmzQISb_tYlZ6DHFNh3CqHRSRXg1wUyEU5uahNQD7v2qwGBo4Ha5-i6HY1kT3b_dG018orIzQHFGfKKmLcMI0ustDgCsVg27hlsgrIJxS8Qh2H1yu1P6oAH4lsWWrKZYy4Nk0DcjyqCbpZjou3Q0d529Cp_UgOyIddMbbEeLfaNj3WkUKAq53JgIjRkBt92bikXt44fnCZAexkeUC-bAfn_uH_77m3D7_rO_I0QW2BaTsRx-Rg3fb2Pfhj62LilG5CDk_Prn7-gqsZn03c2gb8zpPpX0ZANIE
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4qmGFjASiANEzcOxHSSEyqPast2eWmlvxomdslJJtsmu0P4pfiMzTrKrUNFbr_EjTsaemc8ef0PI65AbLkSgfZ1kgc80AFaZRNzPU-ReB4ti3EXhyQkfnbHv02S6Rf70d2EwrLLXiU5RmyrHPfJ9cNMlpoaPwk_zSx-zRuHpap9Co50WY7v6DZCt-Xj0FeT7JooOv51-GfldVgE_B2O78DmAssAACoiDXEeGIaQoJLNJEWjtRpjxQkTacs1lksVCh1FQCIM7JKmwQQz93iK3GR4xwvoR0w3Ai9I2iS4DZAaGnPWXdCTfb8BWCLwLDeAdg8r81cAQunwBV63C1UjNf45rnRU8fEDud-4rPWjn20OyZctH5M6kO6B_TGrQNxjmbg3FoHVaFfQXePrnSOuxorOSdjyuDcUNYNrySM9yerGcLxtq61VLIls1y-YDna-Ti_mZ6xKz-dYL6ihxsbNxBe96Qs5uRABPyXZZlXaHUFsgYVggNSgqpsMiZUYyQEyZlqkxceKRsP_HKu84zzH1xoVy2Edy1cpFgVyUk4taeeTdus28Zfy4tvZnFN26JrJ1uwdVfa66xQ_NATWavAgYN0yjSy40uF4h6FJumSw88hYFr1CnwPBy3V2NgI9Edi51wGWIODqOPbI3qAm6IB8W91NHdbqoUZuV45FX62JsifF1pa2WWEcKAa59Ij0iBlNu8GXDknL20_GRywRgLks98r6fnJuX___PPbt-rC_J3dHp5FgdH52Md8m9CFcOuAyR2CPbi3ppn4MvuMheuAVIyY-bXvF_AddravU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXxFOEFjASEgeImodjO9yWx6pQWnFgpd4sJ7bLSiVZ5XHYf98ZJ1kIBSSu8Tiv8Yzns2c-E_Iy5oYLEelQZ0UUMg2AVWYJD8scuddhRjG-UPj0jB-v2Ofz7PyXKn6f7T5tSQ41DcjSVHVHG-MGE5f8qAXPK7CyGKAwpmiF25vkFoO5GpO6VsliB7kSgBdTqcwf-82mI8_af903X8-X_G3T1M9Fy7vkzhhE0sWg9Xvkhq3uk_3TcZv8AWnA6jHZ3BqKqeO0dvQHxNsXSK6xpeuKjmyqLcVlWDqwOa9Letlv-pbaZjtQudZt376lm90RX2Hhb4ln6jYd9cS0eLOTGp71kKyWH7-9Pw7HwxXCEmKOLuSATSMDYCiNSp0YhsjKSWYzF2ntFVVwJxJtueYyK1Kh4yRywuBCUS5slD4ie1Vd2ceEWoe0XZHU4C6Yjl3OjGSAWwotc2PSLCDx9I9VOTKP4wEYl8ojEMnVoBcFelFeL2obkNe7PpuBd-Of0u9QdTtJ5Mz2F-rmQo0mCN0Bu5nSRYwbpjEwFhoCoBg8GrdMuoC8QsUrtGx4vVKPBQrwkciRpRZcxohm0zQghzNJsMhy3jwNHTV6hFYBzJQQG6ZJHJAXu2bsiVlula17lJFCQICdyYCI2ZCbfdm8pVp_96zgMgOwyfKAvJkG58-H__3PPfk_8edk_-uHpfry6ezkgNxOcO0hxvKuQ7LXNb19CgFaVzzzNngFNnQy8w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+risk+of+malignancy+in+patients+with+systemic+lupus+erythematosus%3A+population-based+cohort+study+in+Korea&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Han%2C+Jung-Yong&rft.au=Kim%2C+Hyoungyoung&rft.au=Jung%2C+Sun-Young&rft.au=Jang%2C+Eun+Jin&rft.date=2021-10-27&rft.issn=1478-6362&rft.eissn=1478-6362&rft.volume=23&rft.issue=1&rft.spage=270&rft_id=info:doi/10.1186%2Fs13075-021-02648-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon